Barclays raised the firm’s price target on CVS Health (CVS) to $82 from $73 and keeps an Overweight rating on the shares following the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health Reports Strong Q1 2025 Results
- CVS Health’s Q1 2025 Earnings Call: Strong Results and Optimistic Outlook
- U.S. files False Claims Act complaint against three insurers, three brokers
- U.S. files False Claims Act complaint against Elevance, Humana, Aetna
- Early notable gainers among liquid option names on May 1st